CD44 and breast cancer: McClements et al. reported that treatments of breast cancer cells (MCF-7, MDA-MB-231, ZR-75 cell lines) with an FKBPL peptide derivative, AD-01, reduce the populations of CD44-positive CSCs and their ability to form mammospheres [178].